Houston, United States
Research view
Mantle cell lymphoma: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
- All targets
- CD19 20
- BTK 17
- CD20 8
- TP53 2
- BCL-2 5
- PI3K 0
- CD22 3
- MYC 0
- PD-1 2
- CXCR4 0
- EGFR 0
- PD-L1 1
- PRMT5 0
- ALK 0
- CD47 0
- JAK 0
- STAT3 0
- AKT 0
- ATM 0
- BRCA1 1
- BRCA2 1
- BRD4 0
- CCR5 0
- CD40 0
- FLT3 0
- GPX4 0
- HDAC 0
- HSP90 0
- KMT2A 0
- MET 0
- mTOR 0
EU-13 is a filter, not a ranking: it only narrows the list.
Rochester, United States
Duarte, United States
Munich, Germany
New York, United States
Munich, Germany
Tampa, United States
Boston, United States
New York, United States
Columbus, United States
Stanford, United States
Paris, France
Barcelona, Spain
Seattle, United States
Cleveland, United States
Philadelphia, United States
Barcelona, Spain
Paris, France
Bologna, Italy
Beijing, China
Verona, Italy
Beijing, China
Warsaw, Poland
Turin, Italy
24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Terminated
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
“The trial closed early due to slow accrual.”Registry text, quoted unchanged. Source
Terminated
“The study sponsor withdrew funding early, forcing this study to stop all activity and close pre-maturely.”Registry text, quoted unchanged. Source
Terminated
“No longer a research question to answer.”Registry text, quoted unchanged. Source
Terminated
“Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.”Registry text, quoted unchanged. Source
Terminated
“Business reasons, not related to safety or efficacy results.”Registry text, quoted unchanged. Source
Terminated
“Financial reasons”Registry text, quoted unchanged. Source
Terminated
TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
“Study terminated for strategic business reasons”Registry text, quoted unchanged. Source
Terminated
“Manufacturing issues”Registry text, quoted unchanged. Source
Terminated
A Phase 1 Study of ADI-001 in B Cell Malignancies
“Terminated - Halted Prematurely”Registry text, quoted unchanged. Source
Terminated
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
“Slow accrual rate”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.